Seeing Is Believing
Currently out of the existing stock ratings of Alethia Young, 255 are a BUY (79.69%), 59 are a HOLD (18.44%), 6 are a SELL (1.88%).
Analyst Alethia Young, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 61% that have a potential upside of 50.54% achieved within 370 days.
Alethia Young’s has documented 614 price targets and ratings displayed on 53 stocks. The coverage is on Healthcare, Basic Materials sectors.
Most recent stock forecast was given on RCUS, Arcus Biosciences at 04-Jul-2024.
Analyst best performing recommendations are on CLVS (CLOVIS ONCOLOGY).
The best stock recommendation documented was for BIIB (BIOGEN) at 11/3/2020. The price target of $278 was fulfilled within 1 day with a profit of $30.99 (12.55%) receiving and performance score of 125.46.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
$2
$1.82 (1011.11%)
$5
6 years 5 months 9 days ago
(02-May-2019)
2/3 (66.67%)
$-0.96 (-32.43%)
528
Hold
$4
7 years 8 months 4 days ago
(07-Feb-2018)
4/4 (100%)
$-0.81 (-16.84%)
106
Buy
$5
$4.82 (2677.78%)
$6
7 years 10 months 1 days ago
(10-Dec-2017)
0/4 (0%)
$2.14 (74.83%)
Buy
$10
8 years 1 months ago
(11-Sep-2017)
0/2 (0%)
$5.79 (137.53%)
Hold
$4
$3.82 (2122.22%)
$5
8 years 1 months 1 days ago
(10-Sep-2017)
6/7 (85.71%)
$0.17 (4.44%)
49
What Year was the first public recommendation made by Alethia Young?